Signaturefd LLC Decreases Stake in Humana Inc. (NYSE:HUM)

Signaturefd LLC lessened its holdings in Humana Inc. (NYSE:HUM) by 40.3% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,367 shares of the insurance provider’s stock after selling 924 shares during the period. Signaturefd LLC’s holdings in Humana were worth $347,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. FPC Investment Advisory Inc. purchased a new position in Humana in the fourth quarter valued at about $27,000. Centricity Wealth Management LLC bought a new position in Humana during the fourth quarter valued at $30,000. LFA Lugano Financial Advisors SA increased its position in Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares during the last quarter. OFI Invest Asset Management bought a new stake in shares of Humana in the fourth quarter valued at $33,000. Finally, Atwood & Palmer Inc. lifted its position in shares of Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after buying an additional 60 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.37% of the company’s stock.

Humana Stock Performance

Humana stock opened at $266.33 on Friday. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The firm’s fifty day moving average price is $271.33 and its 200-day moving average price is $277.52. The stock has a market cap of $32.14 billion, a P/E ratio of 26.77, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM) last issued its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, equities research analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.33%. The ex-dividend date is Friday, March 28th. Humana’s payout ratio is currently 35.58%.

Wall Street Analyst Weigh In

HUM has been the topic of several recent research reports. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $290.00 price objective on shares of Humana in a report on Wednesday, February 12th. Truist Financial raised their price objective on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Piper Sandler boosted their target price on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. Barclays raised their price target on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a report on Thursday, February 13th. Finally, Morgan Stanley decreased their price objective on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Nineteen analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.